Match Document Document Title
US20120005128 METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION  
The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with...
US20140161918 Use of Adipose Septa Protein Modulators and Compositions Thereof  
Methods of using adipose septa protein modulators to impart anti-aging benefits to the skin and/or improve skin conditions resulting from weakened or compromised adipose septa.
US20120264703 Methods And Compositions For The Treatment Of Anxiety Disorders, Including Post Traumatic Stress Disorder (PTSD) And Related Central Nervous System (CNS) Disorders.  
The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using α and...
US20110039926 USE OF ENANTIOMER (1S, 2R) MILNACIPRAN HYDROCHLORIDE FOR THE PREVENTIVE TREATMENT OF SUICIDAL BEHAVIOUR IN DEPRESSED PATIENTS  
The invention concerns the substantially pure (1S,2R) enantiomer of milnacipran hydrochloride for its use for treating patients suffering from psychiatric disorders, while reducing the risk of...
US20130217615 COMBINATION TREATMENT OF MAJOR DEPRESSIVE DISORDER  
A method is provided for treating depression, and particularly major depression,by administering an effective amount of an SSRI medication that is augmented by administering an effective amount of...
US20150196527 METHOD OF TREATMENT  
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions....
US20130236573 ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION  
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a...
US20110117078 Methods for the Treatment of Cancers  
Methods for the treatment of cancers involving dysregulation of thromboxane receptor β (TP-β) are provided, including in certain aspects methods for diagnosing such cancers. Specific cancers...
US20150119383 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130245004 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20130143867 ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME  
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other...
US20100310599 Orally Bioavailable Lipid-Based Constructs  
The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
US20110009351 SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS  
The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF)...
US20110166220 DRONEDARONE FOR THE PREVENTION OF PERMANENT ATRIAL FIBRILLATION  
Methods of using dronedarone in the prevention of permanent atrial fibrillation.
US20150216837 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20150025086 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20140357710 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20140296332 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20140296331 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20140296330 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20130197076 TREATMENT OF CIRCADIAN RHYTHM DISORDERS  
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind...
US20140088189 METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION  
The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or...
US20120000806 METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION  
The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or...
US20110111009 METHODS AND FORMULATIONS FOR ENHANCING THE ABSORPTION AND DECREASING THE ABSORPTION VARIABILITY OF ORALLY ADMINISTERED DRUGS, VITAMINS AND NUTRIENTS  
A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then...
US20110269762 METHODS FOR TREATING ATRIAL FIBRILLATION AND REDUCING STROKE RATE IN ATRIAL FIBRILLATION PATIENTS  
The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial...
US20100305070 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS  
The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome...
US20150011512 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS  
The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome...
US20140248375 Combination Therapy for Treating Proliferative Diseases  
The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
US20110130367 Combination Therapy for Treating Proliferative Diseases  
The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
US20140271953 Use of Melicope Extracts to Improve Conditions Caused by Excess Lipids  
Methods of using extracts of Melicope to impart anti-lipid benefits to skin and/or improve skin conditions resulting from an over-production of lipids.
US20110144199 METHODS FOR TREATING ATRIAL FIBRILLATION  
The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods...
US20140005260 METHOD FOR INHIBITING CANCER METASTASIS BY AMIODARONE  
Amiodarone inhibits the invagination during zebrafish heart development and makes the defect on valves development. The present invention demonstrates that Amiodarone inhibits cancer metastasis...
US20150057325 COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST  
The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute...
US20130261177 COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST  
The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute...
US20130143861 METHODS FOR TREATING ATRIAL FIBRILLATION  
The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial...
US20150087649 TREATING DISORDERS ASSOCIATED WITH ABERRANT ADRENOCORTICAL CELL BEHAVIOR  
Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC) and/or...
US20140348926 FORMULATION AND METHOD FOR INCREASING ORAL BIOAVAILABILITY OF DRUGS  
The application discloses a formulation and method for increasing bioavailability of an orally administered drug.
US20110195932 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy  
Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various...
US20110293556 TREATMENT OF INSULIN RESISTANCE/METABOLIC SYNDROME TO ALLEVIATE THE RISKS OF DEMENTIA  
This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's...
US20110065757 METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS  
We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability)...
US20130203688 SUGAR PLANT DERIVED BY-PRODUCTS AND METHODS OF PRODUCTION THEREOF  
The present document describes a nutraceutical or cosmeceutical composition for the prophylaxis of an ailment comprising a therapeutically effective amount of a sugar plant syrup filtration...
US20130115294 STABLE LIQUID OILY READY-TO-USE FORMULATIONS, PREPARATION THEREOF AND USE THEREOF  
The present invention relates to a stable liquid oily ready-to-use formulation comprising an active pharmaceutical ingredient, which has hydrophobic and/or lipophilic properties and/or which...
US20110046218 CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE  
The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro -5-isobenzofurancarbonitrile,...
US20150216924 Method of Obtaining Phytochemicals Including Resveratrol and e-Viniferin From Vineyard Waste  
Phytochemicals of the grape, including trans-resveratrol, trans-viniferin, and oligostilibines are obtained from vineyard waste. Also, a dry powder or granular form of food supplement is provided...
US20140193346 HEALTH SUPPLEMENT  
Herbal composition and method for the treatment of inflammatory pain associated with tendonitis, bursitis, arthritis, carpal tunnel syndrome, tennis elbow, plantar fasciitis, sports injuries,...
US20150057320 TRANSTHYRETIN LIGANDS CAPABLE OF INHIBITING RETINOL-DEPENDENT RBP4-TTR INTERACTION FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION, STARGARDT DISEASE, AND OTHER RETINAL DISEASE CHARACTERIZED BY EXCESSIVE LIPOFUSCIN ACCUMULATION  
A method for treating a disease characterized by excessive lipofuscin accumulation in the retina of a mammal afflicted therewith comprising administering to the mammal an effective amount of a...
US20110183990 METHOD OF TREATING ATRIAL FIBRILLATION  
The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of...
US20110009370 METHOD TO ENHANCE TISSUE REGENERATION  
The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by...
US20130116308 CD36 INHIBITION TO CONTROL OBESITY AND INSULIN SENSITIVITY  
The disclosure relates to the therapeutic utility of CD36 antagonists to reduce body weight, inhibit fat accumulation and especially visceral fat accumulation, improve insulin sensitivity, lower...
US20090191283 TREATMENT OF HEADACHES, NECK PAIN, JOINT PAIN AND INFLAMMATORY-TYPE PAIN  
The formulation provides a method of treating headaches, neck, joint and inflammatory-type pain in a mammalian subject by administering to the subject a therapeutically effective amount of a...